AI diagnostic tools trained on millions of medical images have demonstrated accuracy rates in detecting early-stage lung cancer and diabetic retinopathy that match or exceed those of experienced specialists. Several major hospital systems in the US and UK have integrated these tools into their standard screening workflows, reducing diagnostic delays by weeks in some cases.
Regulatory approval remains a bottleneck. The FDA has cleared fewer than 700 AI-enabled medical devices to date, a fraction of the thousands developed and seeking authorization. Physicians emphasize that AI serves best as a second opinion tool rather than a replacement for clinical judgment, particularly in cases involving complex patient histories and competing conditions.
